---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043851"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:17:26.366688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Q3 revenue $12.3M, record test volume, swings to profit

## Summary
- Q3 net revenue $12.3M, up 35% YoY ($9.1M); test volume up 26% to record levels.
- Operating income $1.9M vs operating loss of $0.02M a year ago; adjusted EBITDA $2.1M vs $0.4M.
- Income from continuing ops $1.4M vs loss of $0.5M; gross margin 61% up from 55%.
- Cash collections $11.3M (+15% YoY); cash $2.1M after $6.6M debt paydown; 18th consecutive quarter of YoY volume growth.
- Company interviewing equity research partners and investment bankers for capital raise and potential Nasdaq listing.

## SEC filing metadata
- accession: 0001493152-24-043851
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315224043851/0001493152-24-043851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315224043851/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043851
- JSON: https://secwatch.observer/filing/0001493152-24-043851.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.